Q4 Financial Results: Comparing Abbott Laboratories (NYSE:ABT) With Other Diversified Medical Devices & Supplies Stocks

Medical Devices & Supplies: Q4 Earnings Overview

As earnings season wraps up, it's an opportune moment to explore fresh investment opportunities and evaluate how companies are navigating today’s market. Here’s a summary of how Abbott Laboratories (NYSE:ABT) and other diversified medical device and supply companies performed in the fourth quarter.

Industry Insights

The medical devices sector is characterized by consistent demand, but it also requires substantial spending on research, development, and regulatory compliance. Companies in this space benefit from ongoing revenue through consumables, maintenance, and technology upgrades. However, high development costs, lengthy approval processes, and the need for clinical validation can impact both profitability and timelines. The industry also faces ongoing pricing pressures as healthcare systems and insurers strive for cost efficiency.

Looking ahead, an aging population is expected to drive increased demand for medical treatments and monitoring. Innovations in digital health, such as remote monitoring and smart devices, are likely to further stimulate growth by accelerating technology adoption. On the flip side, tighter reimbursement policies and the shift toward value-based care models present challenges. Additionally, as more devices become connected, cybersecurity concerns add another layer of complexity for manufacturers.

Q4 Performance Snapshot

Among the six diversified medical device and supply companies tracked, fourth-quarter results were mixed. Collectively, revenue surpassed analyst forecasts by 1.9%, while guidance for the next quarter was generally in line with expectations.

Despite these results, share prices have struggled, with the group’s average stock price down 5.1% since the latest earnings announcements.

Q4 Laggard: Abbott Laboratories (NYSE:ABT)

Founded in 1888 by Dr. Wallace Abbott, Abbott Laboratories has grown into a global healthcare leader, offering a wide array of products spanning medical devices, diagnostics, nutrition, and branded generics.

For the fourth quarter, Abbott Laboratories posted revenue of $11.46 billion, a 4.4% increase year over year. However, this figure was 2.9% below analyst expectations, marking a challenging quarter with notable shortfalls in both total and organic revenue compared to forecasts.

Robert B. Ford, Abbott’s chairman and CEO, commented, “In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future.”

Abbott Laboratories Total Revenue

Abbott’s performance was the weakest among its peers relative to analyst projections. The company’s stock has declined 9.6% since the earnings release and is currently trading at $109.17.

Q4 Standout: Neogen (NASDAQ:NEOG)

Established in 1981, Neogen operates at the crossroads of food safety and animal health, producing diagnostic tools to detect hazardous substances in food and pharmaceuticals for animal care.

Neogen reported fourth-quarter revenue of $224.7 million, a 2.8% decrease from the previous year, but still exceeded analyst estimates by 7.2%. The company delivered a strong quarter, surpassing both EPS and revenue expectations.

Neogen Total Revenue

Neogen led its peer group with the largest beat versus analyst forecasts. The market responded positively, sending the stock up 33.8% since the report, now trading at $9.87.

Baxter International (NYSE:BAX)

Founded in 1931, Baxter International serves hospitals and clinics in over 100 countries with essential healthcare products, including dialysis therapies, IV solutions, infusion systems, surgical equipment, and patient monitoring technologies.

Baxter’s fourth-quarter revenue reached $2.97 billion, up 8% year over year and 5.7% above analyst expectations. Despite this, the company missed full-year EPS guidance and quarterly EPS estimates, resulting in a less favorable quarter overall.

The stock has dropped 19.4% since the earnings announcement and is currently priced at $17.95.

CooperCompanies (NASDAQ:COO)

Since 1958, CooperCompanies has specialized in medical devices for vision care—primarily contact lenses—and women’s health, including fertility products and services.

CooperCompanies reported revenue of $1.02 billion for the quarter, a 6.2% increase year over year, matching analyst expectations. The company also delivered a strong beat on full-year EPS guidance, though organic revenue was in line with forecasts.

CooperCompanies raised its full-year guidance more than any of its peers. The stock is down 8.3% since the earnings release and is trading at $73.51.

Stryker (NYSE:SYK)

Stryker’s innovative medical technologies impact over 150 million patients annually, with products spanning orthopedics, surgical instruments, neurotechnology, and patient care solutions.

For the fourth quarter, Stryker generated $7.17 billion in revenue, an 11.4% year-over-year increase and 0.8% above analyst expectations. The company also narrowly beat organic revenue forecasts, marking a solid quarter.

Stryker’s stock has fallen 2.4% since the earnings report and is currently valued at $345.68.

Explore Top Growth Stocks

Looking to invest in companies with strong fundamentals? Check out our Top 5 Growth Stocks—these businesses are well-positioned for expansion, regardless of market or political shifts.

The StockStory analyst team, comprised of experienced investment professionals, leverages quantitative analysis and automation to deliver timely, high-quality market insights.